Latest News

Omnicom to acquire BioPharm Communications

Omnicom to acquire BioPharm Communications

Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.

Five things for pharma marketers to know: Thursday, May 5, 2016

Five things for pharma marketers to know: Thursday, May 5, 2016

U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers

Time is running out: Fill in MM&M's Agency questionnaire

Time is running out: Fill in MM&M's Agency questionnaire

Did your agency report record growth in 2015? Tell us why when you fill out the A-to-Z questionnaire for MM&M's upcoming agency issue. The deadline is Friday.

Five things for pharma marketers to know: Wednesday, May 4, 2016

Five things for pharma marketers to know: Wednesday, May 4, 2016

The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign

Five things for pharma marketers to know: Tuesday, May 3, 2016

Five things for pharma marketers to know: Tuesday, May 3, 2016

IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service

Five things for pharma marketers to know: Monday, May 2, 2016

Five things for pharma marketers to know: Monday, May 2, 2016

Express Scripts to roll out pricing response program; the FDA approves new Parkinson's disease treatment; Regeneron's plaque psoriasis drug hits endpoint

Five things for pharma marketers to know: Friday, April 29, 2016

Five things for pharma marketers to know: Friday, April 29, 2016

Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

The drugmaker said it plans to increase its investment in DTC for the immuno-oncology drug.

Five things for pharma marketers to know: Thursday, April 28, 2016

Five things for pharma marketers to know: Thursday, April 28, 2016

Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug

Senate committee condemns Valeant's business model

Senate committee condemns Valeant's business model

The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.